Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.61 |
| ▸ | HTR3A | P46098 | 2/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.58 |
| ▸ | HTR6 | P50406 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | NOS3 | P29474 | 1/20 | 0.51 |
| ▸ | NOS1 | P29475 | 1/20 | 0.51 |
| ▸ | NOS2 | P35228 | 1/20 | 0.51 |
| ▸ | EP300 | Q09472 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1474997 | 0.98 | SLC6A2 (0.60) | SLC6A2SLC6A4HTR3AKCNH2SLC6A3 | |
| SCHEMBL9923476 | 0.91 | SLC6A2 (0.63) | SLC6A2SLC6A4HTR3AKCNH2SLC6A3 | |
| SCHEMBL26668494 | 0.89 | SLC6A2 (0.71) | SLC6A2SLC6A4HTR3AKCNH2SLC6A3 | |
| SCHEMBL27991135 | 0.89 | TLR4 (0.49) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30441849 | 0.89 | TLR4 (0.49) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2300124 | 0.84 | SLC6A2 (0.48) | SLC6A2SLC6A4HTR3AKCNH2SLC6A3 | |
| SCHEMBL27996084 | 0.84 | PARP10 (0.52) | — | |
| SCHEMBL12420658 | 0.83 | MAOB (0.56) | SLC6A2SLC6A4HTR3AKCNH2SLC6A3 | |
| SCHEMBL13107011 | 0.82 | SLC6A2 (0.53) | SLC6A2SLC6A4SLC6A3HTR6 | |
| Hydrochloric Acid SCHEMBL16823666 | 0.81 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12268687-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-08 | — | — | US | disclosed |
| US-20250034124-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-30 | — | — | US | disclosed |
| US-20250034125-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-30 | — | — | US | disclosed |
| US-12098146-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-24 | — | — | US | disclosed |
| US-20230116101-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| CN-113906019-A | Compound and use thereof | 优曼尼蒂治疗公司 | 2022-01-07 | — | — | CN | disclosed |
| EP-3914593-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| WO-2021097240-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021097240-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20210139471-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-13 | — | — | US | disclosed |
| US-7915274-B2 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-29 | — | — | US | disclosed |
| CN-100389113-C | Nitrogen-containing heterocyclic compound and drug containing same | EISAI CO LTD (JP) | 2008-05-21 | — | — | CN | disclosed |
| US-20070293496-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | OZAKI FUMIHIRO | 2007-12-20 | — | — | US | disclosed |
| US-7265108-B2 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| EP-1484327-B1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINE THEREOF | EISAI R&D MAN CO LTD (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-6995144-B2 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI CO., LTD. (JP) | 2006-02-07 | — | — | US | disclosed |
| US-20050245527-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| CN-1630650-A | Nitrogen-containing heterocyclic compound and drug containing same | EISAI CO LTD (JP) | 2005-06-22 | — | — | CN | disclosed |
| EP-1484327-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINE THEREOF | Eisai Co., Ltd. (JP) | 2004-12-08 | — | — | EP | disclosed |
| US-20040167224-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293496-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | XDH, NQO1, CYP1A1 | SLC6A2 1216/4885SLC6A4 826/4885HTR3A 1189/4885 |
| US-20250034124-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | SLC6A2 520/4885SLC6A4 451/4885HTR3A 2200/4885 |
| US-12268687-B2 | Compounds and uses thereof | NLN, BDNF, NQO1 | SLC6A2 520/4885SLC6A4 451/4885HTR3A 2200/4885 |
| US-20230116101-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | SLC6A2 520/4885SLC6A4 451/4885HTR3A 2200/4885 |
| US-20250034125-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | SLC6A2 520/4885SLC6A4 451/4885HTR3A 2200/4885 |
| US-20210139471-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | SLC6A2 520/4885SLC6A4 451/4885HTR3A 2200/4885 |
| US-20040167224-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | NQO1, CBR1, NOX1 | SLC6A2 1196/4885SLC6A4 789/4885HTR3A 1639/4885 |
| US-12098146-B2 | Compounds and uses thereof | NLN, BDNF, NQO1 | SLC6A2 520/4885SLC6A4 451/4885HTR3A 2200/4885 |
| US-20050245527-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | XDH, NQO1, CYP1A1 | SLC6A2 1216/4885SLC6A4 826/4885HTR3A 1189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.